PGEN

Precigen (PGEN)

About Precigen (PGEN)

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Details

Daily high
$0.90
Daily low
$0.86
Price at open
$0.89
52 Week High
$1.93
52 Week Low
$0.82
Market cap
259.8M
Dividend yield
0.00%
Volume
264,957
Avg. volume
778,196
P/E ratio
-1.67

Precigen News

Details

Daily high
$0.90
Daily low
$0.86
Price at open
$0.89
52 Week High
$1.93
52 Week Low
$0.82
Market cap
259.8M
Dividend yield
0.00%
Volume
264,957
Avg. volume
778,196
P/E ratio
-1.67